Sanofi wins EU green light for new MS drug Lemtrada
LONDON, June 28
LONDON, June 28 (Reuters) - French firm Sanofi has won a European green light for its new multiple sclerosis medicine Lemtrada, after a quarter-century drug development saga.
Lemtrada, also known as alemtuzumab, has been studied in multiple sclerosis (MS) since the early 1990s but its progress to market as a treatment for the disease has been halting and the drug has changed hands many times.
The European Medicines Agency said on Friday it was recommending Lemtrada for relapsing-remitting MS. EMA decisions are usually endorsed by the European Commission within a couple of months. (Reporting by Rosalba O'Brien and Caroline Copley)
- Malaysian plane presumed crashed; questions over false IDs |
- CORRECTED-UPDATE 4-Malaysia Airlines plane crashes in South China Sea with 239 people aboard - report
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Warning shots fired to turn monitors back from Crimea |
- Malaysian plane crashed off Vietnam coast: state media